Physician profile
Aron S Adkins
NPI 1336246529
$349,258.70
in general payments reported to CMS, 2019-2025
20 companies · $49K in 2025
The $49K reported for 2025 was more than what 96% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90K · 2020: $36K · 2021: $61K · 2022: $50K · 2023: $43K · 2024: $21K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $48K · Food and Beverage: $4,964 · Travel and Lodging: $4,176 · Consulting Fee: $750 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,477.94 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $48,443.00 |
| Food and Beverage | $4,963.81 |
| Travel and Lodging | $4,175.73 |
| Consulting Fee | $750.00 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $169,752.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $58,050.04 | 2022-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $40,726.82 | 2019-2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $25,993.57 | 2021-2025 | |
| Abbott Laboratories | $16,216.53 | 2019-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $13,839.30 | 2019-2020 | |
| Medtronic Minimed, INC. | $13,061.28 | 2019-2020 | |
| Medtronic, INC. | $6,005.66 | 2021 | |
| Cequr Corporation | $5,153.65 | 2022-2024 | Cequr Simplicity |
| Tandem Diabetes Care, INC. | $135.78 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Companion Medical, INC. | $100.27 | 2020 | |
| Corcept Therapeutics | $60.34 | 2025 | Korlym |
| Amgen INC. | $43.87 | 2024 | Tepezza |
| Lilly USA, LLC | $28.08 | 2022-2025 | Jardiance |
| Sequel Med Tech, LLC | $22.14 | 2025 | Twiist |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuity Medical INC | $19.04 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Ascensia Diabetes Care US INC. | $15.37 | 2021 | |
| Horizon Therapeutics Plc | $13.09 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.42 | 2019 | |
| Senseonics, Incorporated | $10.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aron Adkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.